Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials

Autor: Matthias Groschek, Corinne Vannier, Sina Grebhardt, Hans Ulrich Siebenbach, Ulrike Söling, Tobias Dechow, Timo Behlendorf, Ali Aldaoud, Karin Potthoff, Wolfgang Knauf, Henning Eschenburg, Richard A. Hansen
Rok vydání: 2021
Předmět:
Zdroj: European Journal of Haematology. 108:133-144
ISSN: 1600-0609
0902-4441
DOI: 10.1111/ejh.13719
Popis: Background Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor and treatment options are limited. While pomalidomide plus low-dose dexamethasone (POM/DEX) has demonstrated efficacy in clinical trials, real-word evidence is scarce. Patients and methods POSEIDON was a prospective non-interventional study designed to evaluate effectiveness, safety and quality of life (QoL) of POM/DEX in patients with relapsed or refractory MM (R/RMM) pretreated with at least two prior therapy lines including both lenalidomide and bortezomib in real-world in Germany. Patients received POM/DEX according to physicians' choice. Data were analyzed descriptively. Results Between 2014 and 2017, 151 patients were enrolled, 144 patients with a median of three prior therapy lines qualified for effectiveness analysis. Median age was 73.2 years. Median progression-free and overall survival were 6.3 months [95% confidence interval (CI) 5.2,8.6] and 12.9 months [95% CI 10.6,15.1]. Most frequent grade 3/4 adverse events were leukopenia (8.2%), pneumonia (7.5%), and anemia (5.5%). QoL was maintained after start of POM/DEX. Conclusion The results of POSEIDON support the effectiveness and safety of POM/DEX in R/RMM patients pretreated with lenalidomide and bortezomib and highlight the clinical value of the POM/DEX regimen in the real-world setting.
Databáze: OpenAIRE
Externí odkaz: